Czech National Bank Has $4.46 Million Stock Position in Laboratory Co. of America Holdings (NYSE:LH)

Czech National Bank boosted its position in shares of Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 5.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 19,155 shares of the medical research company's stock after purchasing an additional 1,020 shares during the quarter. Czech National Bank's holdings in Laboratory Co. of America were worth $4,458,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Graney & King LLC purchased a new stake in Laboratory Co. of America during the fourth quarter worth $26,000. Human Investing LLC acquired a new stake in shares of Laboratory Co. of America during the fourth quarter valued at $39,000. Heck Capital Advisors LLC acquired a new stake in shares of Laboratory Co. of America during the fourth quarter valued at $44,000. SBI Securities Co. Ltd. acquired a new stake in shares of Laboratory Co. of America during the fourth quarter valued at $52,000. Finally, Deseret Mutual Benefit Administrators boosted its stake in shares of Laboratory Co. of America by 28.2% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 232 shares of the medical research company's stock valued at $53,000 after acquiring an additional 51 shares during the last quarter. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on LH. Redburn Atlantic began coverage on Laboratory Co. of America in a research note on Wednesday, April 2nd. They set a "buy" rating and a $276.00 price objective on the stock. Wall Street Zen lowered Laboratory Co. of America from a "buy" rating to a "hold" rating in a research note on Friday, April 18th. Truist Financial increased their price objective on Laboratory Co. of America from $274.00 to $290.00 and gave the company a "buy" rating in a research note on Monday, May 12th. Barclays increased their target price on Laboratory Co. of America from $240.00 to $250.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Finally, Robert W. Baird increased their target price on Laboratory Co. of America from $253.00 to $267.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 30th. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $272.92.

Insider Transactions at Laboratory Co. of America

In other Laboratory Co. of America news, EVP Amy B. Summy sold 758 shares of the business's stock in a transaction on Friday, March 28th. The stock was sold at an average price of $231.67, for a total transaction of $175,605.86. Following the completion of the transaction, the executive vice president now owns 5,302 shares in the company, valued at approximately $1,228,314.34. The trade was a 12.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Der Vaart Sandra D. Van sold 1,900 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $238.36, for a total value of $452,884.00. Following the completion of the sale, the executive vice president now owns 2,244 shares of the company's stock, valued at approximately $534,879.84. This trade represents a 45.85% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,592 shares of company stock worth $2,841,820. 0.84% of the stock is currently owned by corporate insiders.

Laboratory Co. of America Trading Down 0.9%

Shares of Laboratory Co. of America stock traded down $2.17 during trading hours on Thursday, reaching $252.20. The stock had a trading volume of 704,283 shares, compared to its average volume of 636,711. The firm has a 50 day simple moving average of $236.48 and a two-hundred day simple moving average of $238.59. The firm has a market capitalization of $21.11 billion, a price-to-earnings ratio of 28.59, a P/E/G ratio of 1.71 and a beta of 0.82. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. Laboratory Co. of America Holdings has a 1 year low of $192.38 and a 1 year high of $258.59.

Laboratory Co. of America (NYSE:LH - Get Free Report) last announced its earnings results on Tuesday, April 29th. The medical research company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.73 by $0.11. The business had revenue of $3.35 billion for the quarter, compared to the consensus estimate of $3.41 billion. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. The company's revenue was up 5.3% on a year-over-year basis. During the same period last year, the business posted $3.68 EPS. As a group, equities research analysts anticipate that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current year.

Laboratory Co. of America Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 11th. Shareholders of record on Thursday, May 29th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.14%. Laboratory Co. of America's dividend payout ratio (DPR) is presently 33.29%.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.